Trial Profile

Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Women's Cancers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Durvalumab (Primary)
Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
Focus Adverse reactions

Most Recent Events

03 Oct 2022 According to a Gradalis media release, data from this study published in Clinical Medicine Insights
03 Oct 2022 Results published in the Gradalis Media Release
26 Jan 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com